

Ecully, April 30, 2026 – 6:00 p.m.

First-quarter 2026 revenue

- **High order volume**
- **Slower-than-expected normalization of supply chains**
- **2026: growth trajectory confirmed**

<i>In thousands of euros</i>	2026	2025	Change as a %
Q1 revenue	2,176	2,828	-23%

Unaudited consolidated data

Spineway, a specialist in innovative implants for the treatment of severe spine disorders, recorded revenue of €2.2 million in the first quarter of 2026.

Following strong growth in the fourth quarter of 2025 (+38%), the slowdown observed in the first quarter of 2026 will not undermine the Group's momentum. It is mainly attributable to delays in regulatory approvals in certain regions and supply delays from subcontractors facing increased demand. These challenges have been identified, contained, and are being resolved.

International export sales (excluding Europe) were mixed:

In **Asia**, business remains solid, with revenue up 3.7% and with growth prospects in Vietnam and Australia.

In the **Middle East**, business is at a temporary standstill against adverse geopolitical backdrop.

In **Latin America**, revenue came in €0.4 million below the previous year, impacted by a slower-than-anticipated ramp-up in deliveries. The Group continues to expand its distribution network in this high-potential region (particularly in Mexico and Brazil), with a view to achieving critical mass.

In **France**, the domestic market remains resilient, with stable revenue supported by prioritized inventory management while in Europe revenue was slightly down.

In a structurally favorable healthcare environment, Spineway continues to expand, notably through the intensification of its multi-year regulatory approval program. With a robust order

backlog, the Group expects the lag between orders and revenue to gradually normalize from the second half of 2026 onwards. This will help offset the quarterly volatility associated with the current growth phase.

Next event:

July 30, 2026 – H1 2026 revenue and results

About Spineway

Spineway designs, manufactures and markets innovative implants and surgical instruments for treating severe disorders of the spinal column.

Spineway has an international network of over 50 independent distributors and more than 70% of its revenue comes from exports.



Spineway is eligible for the PEA-PME (equity savings plans for SMEs)



Listing venue: **Euronext Growth Paris**

ISIN: **FR001400N2P2**

Ticker: **ALSPW**

Find out all about Spineway at www.spineway.com

Contacts:



Spineway

Shareholder-services line

Available Tuesday through Thursday (10 a.m.-12 midday)

+33 (0)806 706 060



Aelium

Investor relations

Isabelle Desmottes

spineway@aelium.fr

This press release has been prepared in both English and French. In case of discrepancies, the French version shall prevail.